Abcam, ab75749, Anti-PACT (PKR activating protein) / PRKRA antibody [EPR3224]

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal PACT (PKR activating protein) / PRKRA antibody. Suitable for IHC-P, WB and reacts with Human samples. Cited in 15 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR3224,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PACT also known as PKR activating protein or PRKRA is a regulator of the protein kinase R (PKR). This protein plays a role in PKR activation stimulating its autophosphorylation. Structurally PACT has a molecular mass of approximately 37 kDa. Researchers observed its expression in many tissues with notable presence in the brain and in immune cells. PACT functions interact with PKR and it also goes by the alternative names PKR activator and PKR protein activator.
Biological function summary
PACT involves in the cellular stress response signaling. It serves as an activator for PKR a kinase that becomes active during viral infections and stress. PACT forms complexes with PKR facilitating its activation and subsequent initiation of downstream signaling cascades. It contributes significantly to the regulation of protein synthesis and cell growth by modulating these pathways. In conditions of stress PACT ensures adequate PKR activation for host defense.
Pathways
PACT is key in the interferon signaling pathway and the stress response pathway. It partners with PKR to suppress protein synthesis through phosphorylation of the eukaryotic initiation factor 2 alpha (eIF2α) which slows down protein production during cellular stress. This interaction places PACT at a junction of antiviral defense and stress adaptation with PKR serving as an essential protein involved in these pathways.
PACT links to conditions such as Huntington’s disease and dystonia. Dysregulation in PACT's function impacts these neurodegenerative disorders as it relates to its role in stress response. Altered interactions between PACT and PKR contribute to neuronal dysfunction highlighting its importance in these pathologies. Understanding how PACT and its partner proteins like PKR and eIF2α operate can lead to potential therapeutic targets for these diseases.